Rockville, MD – A private, independent review body for medical diagnostics is gearing up to grow from one of Montgomery County’s Innovation Centers to a larger space in the County.

Scheer Partners, the leading provider of fully integrated commercial real estate services for the health science industry in the Washington and Baltimore metropolitan areas, announces today that it has negotiated on behalf of United States Diagnostics Standards (“USDS”) in a 10,000-square-foot lease at 9712 Medical Center Drive, which is part of a five-building, 215,174-square-foot complex owned by San Diego-based BioMed Realty Trust.

In this long-term lease relocation, Scheer Partners Senior Vice Presidents Henry Bernstein and Matt Brady represented USDS, which currently resides in the Rockville Innovation Center at 155 Gibbs St. Brady says that USDS expects to occupy its new Rockville home over the next several months.

“USDS sought to locate in the Shady Grove Life Sciences Center, so we’re extremely pleased to have completed this transaction for our client at 9712 Medical Center Drive,” he says. “The company plans to ramp up its work force from only a handful of employees to about 20 professionals in the near term, and its new corporate headquarters provides it with ample room to grow.”

Founded in 2009 by Jeffrey Cossman, its president and chairman, USDS provides third-party certification and evaluation of diagnostics for, among others, clinical laboratories, manufacturers of diagnostics, payers and pharmaceutical companies.

The company certifies the performance, clinical use and risks of diagnostic tests through its DxSTANDARDS™ process, using standards and methods based on the consensus of leading independent experts in medical diagnostics and clinical medicine.

Cossman, an internationally recognized leader in the field of diagnostics, previously served as the chairman of the Department of Pathology at Georgetown University and also as the Oscar B. Hunter Professor of Pathology there.

Earlier in this career, he founded one of the nation’s first molecular diagnostic labs while at the National Cancer Institute, where he developed and implemented lymphoma molecular diagnostic tests now in use worldwide.

Menlo Park, Calif.-based InterWest Partners is the lead investor in USDS, and the company’s advisers include Mark McClellan, who is the former commissioner of the U.S. Food and Drug Administration as well as the former administrator of the U.S. Centers for Medicare & Medicaid Services.